Elisabeth Castellanos1, Adrià Plana2, Cristina Carrato3, Meritxell Carrió1, Inma Rosas1, Emilio Amilibia4, Francesc Roca-Ribas4, Cristina Hostalot5, Alicia Castillo6, Andrea Ros6, Ariadna Quer3, Juan Luis Becerra7, Hector Salvador8, Conxi Lázaro9, Ignacio Blanco6, Eduard Serra1, Isabel Bielsa2. 1. Hereditary Cancer Group IGTP-CIBERONC, Program of Predictive and Personalized Medicine of Cancer (PMPPC), Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Barcelona, Spain. 2. Department of Dermatology, Germans Trias i Pujol Hospital (HUGTiP), Can Ruti Campus, Badalona, Barcelona, Spain. 3. Department of Pathology, HUGTiP and Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain. 4. Department of Otorhinolaryngology, HUGTiP, Can Ruti Campus, Badalona, Barcelona, Spain. 5. Department of Neurosurgery, HUGTiP, Can Ruti Campus, Badalona, Barcelona, Spain. 6. Clinical Genetics and Genetic Counseling Program, HUGTiP, Can Ruti Campus, Badalona, Barcelona, Spain. 7. Department of Neurology, HUGTiP, Can Ruti Campus, Badalona, Barcelona, Spain. 8. Pediatric Oncology Unit, Hospital Sant Joan de Déu, Esplugues, Barcelona, Spain. 9. Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL-CIBERONC), L'Hospitalet de Llobregat, Barcelona, Spain.
Abstract
Importance: Neurofibromatosis type 2 (NF2) is a devastating genetic condition characterized by the development of multiple tumors of the nervous system. An early diagnosis of individuals with NF2 would facilitate treatment and reduction of disease impact because most severe effects of the disease do not usually develop before adolescence. Little attention has traditionally been paid to dermatological signs in NF2. However, skin plaques are commonly seen in patients with NF2, normally appearing either at birth or early childhood, providing an opportunity for early NF2 detection and testing. Objective: To determine the clinical utility of skin plaque identification and characterization in children for reaching an early diagnosis of patients with NF2 and to evaluate their molecular pathogenesis and their use in the genetic diagnostics of NF2. Design, Setting, and Participants: Diagnostic test study by the histological and genetic characterization of skin plaques from patients with NF2. Patients were 7 individuals with NF2 or clinical suspicion of NF2 treated at the Spanish Reference Center on Phakomatoses. Main Outcomes and Measures: Histological evaluation of all skin plaques was performed. Fresh skin plaques were cultured to obtain Schwann cells and the NF2 gene was genetically analyzed. For all 7 patients, NF2 clinical history was reviewed. Results: In all 7 patients (4 male and 3 female), all skin plaques analyzed were histologically characterized as plexiform schwannomas. Genetic analysis of primary Schwann cell cultures derived from them allowed the identification of a constitutional and a somatic NF2 mutation. Genetic testing allowed the early diagnosis of NF2 in a child only exhibiting the presence of skin plaques. Most of the patients with NF2 analyzed had an early presentation of skin plaques and a severe NF2 phenotype. Conclusions and Relevance: This work emphasizes the clinical utility of a careful dermatological inspection and the correct identification of skin plaques in children for an early diagnosis of NF2. We show for the first time that Schwann cells derived from skin plaque plexiform schwannomas bear the double inactivation of the NF2 gene and thus constitute an excellent source of tissue for genetic testing, especially in the context of mosaicism.
Importance: Neurofibromatosis type 2 (NF2) is a devastating genetic condition characterized by the development of multiple tumors of the nervous system. An early diagnosis of individuals with NF2 would facilitate treatment and reduction of disease impact because most severe effects of the disease do not usually develop before adolescence. Little attention has traditionally been paid to dermatological signs in NF2. However, skin plaques are commonly seen in patients with NF2, normally appearing either at birth or early childhood, providing an opportunity for early NF2 detection and testing. Objective: To determine the clinical utility of skin plaque identification and characterization in children for reaching an early diagnosis of patients with NF2 and to evaluate their molecular pathogenesis and their use in the genetic diagnostics of NF2. Design, Setting, and Participants: Diagnostic test study by the histological and genetic characterization of skin plaques from patients with NF2. Patients were 7 individuals with NF2 or clinical suspicion of NF2 treated at the Spanish Reference Center on Phakomatoses. Main Outcomes and Measures: Histological evaluation of all skin plaques was performed. Fresh skin plaques were cultured to obtain Schwann cells and the NF2 gene was genetically analyzed. For all 7 patients, NF2 clinical history was reviewed. Results: In all 7 patients (4 male and 3 female), all skin plaques analyzed were histologically characterized as plexiform schwannomas. Genetic analysis of primary Schwann cell cultures derived from them allowed the identification of a constitutional and a somatic NF2 mutation. Genetic testing allowed the early diagnosis of NF2 in a child only exhibiting the presence of skin plaques. Most of the patients with NF2 analyzed had an early presentation of skin plaques and a severe NF2 phenotype. Conclusions and Relevance: This work emphasizes the clinical utility of a careful dermatological inspection and the correct identification of skin plaques in children for an early diagnosis of NF2. We show for the first time that Schwann cells derived from skin plaque plexiform schwannomas bear the double inactivation of the NF2 gene and thus constitute an excellent source of tissue for genetic testing, especially in the context of mosaicism.
Authors: M Ruggieri; P Iannetti; A Polizzi; I La Mantia; A Spalice; O Giliberto; N Platania; A L Gabriele; V Albanese; L Pavone Journal: Neuropediatrics Date: 2005-02 Impact factor: 1.947
Authors: Adam Hexter; Adrian Jones; Harry Joe; Laura Heap; Miriam J Smith; Andrew J Wallace; Dorothy Halliday; Allyson Parry; Amy Taylor; Lucy Raymond; Adam Shaw; Shazia Afridi; Rupert Obholzer; Patrick Axon; Andrew T King; Jan M Friedman; D Gareth R Evans Journal: J Med Genet Date: 2015-08-14 Impact factor: 6.318
Authors: A Plana-Pla; B García; M Munera-Campos; N Catasus; E Serra Arenas; I Blanco; E Castellanos Perez; I Bielsa Journal: J Eur Acad Dermatol Venereol Date: 2022-05-21 Impact factor: 9.228